KR101680840B1 - Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients - Google Patents
Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients Download PDFInfo
- Publication number
- KR101680840B1 KR101680840B1 KR1020160025104A KR20160025104A KR101680840B1 KR 101680840 B1 KR101680840 B1 KR 101680840B1 KR 1020160025104 A KR1020160025104 A KR 1020160025104A KR 20160025104 A KR20160025104 A KR 20160025104A KR 101680840 B1 KR101680840 B1 KR 101680840B1
- Authority
- KR
- South Korea
- Prior art keywords
- pain
- present
- composition
- preventing
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 239000004480 active ingredient Substances 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 title claims description 33
- 241000533367 Cnidium officinale Species 0.000 title claims description 6
- 208000002193 Pain Diseases 0.000 title abstract description 109
- 230000036407 pain Effects 0.000 title abstract description 104
- 235000013305 food Nutrition 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 241000219104 Cucurbitaceae Species 0.000 claims description 3
- 230000002085 persistent effect Effects 0.000 claims 2
- 235000009849 Cucumis sativus Nutrition 0.000 claims 1
- 240000008067 Cucumis sativus Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 235000019206 astragalus extract Nutrition 0.000 abstract description 6
- 238000010253 intravenous injection Methods 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 238000010171 animal model Methods 0.000 description 12
- 208000004454 Hyperalgesia Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000008533 pain sensitivity Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 235000006533 astragalus Nutrition 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 241001061264 Astragalus Species 0.000 description 5
- 206010065390 Inflammatory pain Diseases 0.000 description 5
- 208000001294 Nociceptive Pain Diseases 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000004233 talus Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000184734 Pyrus japonica Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000238814 Orthoptera Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229910052956 cinnabar Inorganic materials 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 210000004345 peroneal nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 210000001032 spinal nerve Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 101100327310 Caenorhabditis elegans emb-27 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000371022 Ornithoptera Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- 208000000399 Procedural Pain Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100033121 Transcription factor 21 Human genes 0.000 description 1
- 101710119687 Transcription factor 21 Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 fluoroalkane Chemical compound 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229940020463 prialt Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 210000001590 sural nerve Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
Abstract
본 발명은 천궁 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물을 제공한다. 본 발명의 조성물은 기 발생된 통증에 대해 완화 및 치료 효과를 가질 뿐 아니라 통증이 발생하기 이전에 대상에 투여하면 통증을 예방하는 효과를 나타낸다. 본 발명의 조성물은 정맥주사 또는 피부 도포 등의 방법이 아닌 경구 투여를 통해서도 현저한 통증 완화 효과를 나타내며, 이러한 특징을 갖는 본 발명의 조성물은 식품에 적용 가능성이 높다. The present invention provides a composition for alleviating, preventing or treating pain comprising astragalus extract as an active ingredient. The composition of the present invention not only alleviates and treats the pain generated, but also has an effect of preventing pain when administered to a subject before pain occurs. The composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics is highly applicable to foods.
Description
본 발명은 천궁 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for alleviating, preventing or treating pain comprising astragalus extract as an active ingredient.
현재, 진통제로는 아스피린이나 타이레놀 등의 소염진통제가 주류를 이루며, 심한 통증의 경우 모르핀 약물들이 대부분 사용되고 있다. 최근 새로운 통증 억제제를 개발하고 있는데, 통증 치료제 전문 개발사인 자벨린 파마슈티컬스(Javelin Pharmaceuticals)는 중증 수술 후 통증의 치료에 정맥주사 모르핀과 대등한 진통효과를 나타내는 뿌리는 마약성 진통제인 비강 내 모르핀 분무제 ‘릴로민’(Rylomine)을 개발하였다. 또한, 아일랜드 제약회사인 이랜(Elan)이 바다 달팽이독으로부터 개발한 진통제 ‘프라이얼트(Prialt)’가 영국에서 첫 시판되었다.Currently, analgesics such as aspirin and tylenol are the mainstream analgesics, and in the case of severe pain, most of the morphine drugs are used. Javelin Pharmaceuticals, a specialist in pain medicine, is developing a new pain-relieving drug, and its roots, which show analgesic effects equivalent to intravenous morphine for the treatment of pain after severe surgery, Rylomine was developed. In addition, the first painkiller "Prialt" developed by Elan, an Irish pharmaceutical company, was launched in the UK.
만성 악성 종양성 통증은 물론 사회가 고령화됨에 따라 퇴행성 관절염, 요통 관련 질환 환자는 매년 증가 추세에 있으나 모르핀과 같은 기존의 아편제제는 일반인에게 마약작용으로 인하여 사용에 제한이 있어 통증완화제의 수요는 향후 훨씬 더 늘 것으로 예상된다. 또한, 기존의 진통제에 반응하지 않는 통증에 대한 진통제 개발이 크게 요구되고 있고, 진통효과가 상대적으로 큰 것으로 알려진 기존의 아편유사제제 등의 마약성 및 심각한 부작용들로 인해 일반 환자가 편하게 사용할 수 없는 실정이므로 부작용이 없고 진통억제 효능을 갖는 천연자원의 개발이 필요하다.Chronic malignancies As well as benign pains and aging society, patients with degenerative arthritis and back pain-related diseases are on the rise every year. However, existing opioid preparations such as morphine have limited use due to drug action in the general population. Much more is expected. In addition, there is a great demand for the development of analgesics for pain that does not respond to existing analgesic drugs, and because of the narcotic and serious side effects of conventional opioids, which are known to have a relatively high analgesic effect, It is necessary to develop natural resources that have no side effects and have analgesic effect.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명자들은 통증을 효과적으로 완화할 수 있는 인체에 안전한 물질, 특히 식물-유래 물질을 개발하고자 예의 연구 노력하였고, 그 결과 천궁 추출물이 통증을 완화, 예방 또는 치료하는데 매우 유효하다는 것을 규명함으로써, 본 발명을 완성하였다.The inventors of the present invention have sought to develop a safe material, particularly a plant-derived substance, capable of effectively relieving pain, and as a result, it has been found out that the extract of Astragalus membranaceus is very effective for relieving pain, preventing or treating pain, .
따라서 본 발명의 목적은 통증의 완화, 예방 또는 치료용 조성물을 제공하는데 있다.Accordingly, an object of the present invention is to provide a composition for alleviating, preventing or treating pain.
본 발명의 다른 목적은 통증의 완화, 예방 또는 치료용 식품 조성물 및 약제학적 조성물을 제공하는데 있다.Another object of the present invention is to provide a food composition and a pharmaceutical composition for alleviating, preventing or treating pain.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명 및 청구범위에 의해 보다 명확하게 된다. Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention and claims.
본 발명의 일 양태에 따르면, 본 발명은 천궁(Cnidium officinale Makino) 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물을 제공한다. According to one aspect of the present invention, there is provided a composition for alleviating, preventing or treating pain comprising an extract of Cnidium officinale Makino as an active ingredient.
본 발명자들은 통증을 효과적으로 완화할 수 있는 인체에 안전한 물질, 특히 식물-유래 물질을 개발하고자 예의 연구 노력하였고, 그 결과 천궁 추출물이 통증을 완화, 예방 또는 치료하는데 매우 유효하다는 것을 규명하였다.The present inventors have made extensive efforts to develop a safe material for humans, particularly plant-derived materials, which can relieve pain effectively, and as a result, it has been proved that the extract of Cynomolgus sinensis is very effective for alleviating, preventing or treating pain.
본 발명의 조성물은 통증의 완화, 예방 또는 치료에 매우 효과적으로 작용한다. The composition of the present invention is very effective for alleviating, preventing or treating pain.
하기의 실시예에서 입증된 바와 같이, 피부 절개 수술에 앞서 본 발명의 조성물을 동물에 투여한 경우, 수술 부위의 통증 민감도가 감소하였다. As demonstrated in the following examples, when the compositions of the present invention were administered to an animal prior to skin incision surgery, pain sensitivity at the surgical site was reduced.
천궁(Cnidium officinale Makino)은 미나리과(Umbelliferae)에 속하는 다년생 초본으로 중국이 원산지로써 중국, 한국, 일본 등지에서 재배되고 있다. 한방에서는 그 뿌리줄기를 풍냉으로 인한 두통, 동통, 빈혈, 월경불순, 불임 등과 같은 부인과질환의 치료에 이용하고 있다(Lee et al., 2002). 천궁의 생리적작용으로는 항산화(Lee et al., 2002) 및 소염·진통작용(Cho et al., 1996) 그리고 혈소판응집 억제 활성(Zhang L et al., 2009) 등의 보고가 있다. Cnidium officinale Makino is a perennial herb that belongs to the Umbelliferae and is grown in China, Korea, and Japan as its origin. The rootstock is used in the treatment of gynecological diseases such as headache, pain, anemia, menstrual irregularities and infertility due to air-cooling (Lee et al., 2002). The physiological functions of the cynomolgus are reported to be antioxidant (Lee et al., 2002), anti-inflammatory and analgesic action (Cho et al., 1996) and platelet aggregation inhibitory activity (Zhang L et al., 2009).
본 발명의 조성물은 정맥주사 또는 피부 도포 등의 방법이 아닌 경구 투여를 통해서도 현저한 통증 완화 효과를 나타낸다. 이러한 특징을 갖는 본 발명의 조성물은 식품에 잘 적용될 수 있다. The composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration. The composition of the present invention having such characteristics can be applied to foods well.
본 발명의 조성물은 기 발생된 통증에 대해 완화 및 치료 효과를 가질 뿐 아니라 통증이 발생하기 이전에 대상에 투여하면 통증을 예방하는 효과를 나타낸다. The composition of the present invention not only alleviates and treats the pain generated, but also has an effect of preventing pain when administered to a subject before pain occurs.
본 발명의 조성물에서 이용되는 천궁 추출물을 천궁에 추출용매를 처리하여 수득하는 경우에는, 다양한 추출용매가 이용될 수 있다. 본 발명에 따르면, 극성 용매 또는 비극성 용매를 이용할 수 있다. 극성 용매로서 적합한 것은, (i) 물, (ii) 알코올(바람직하게는, 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜), (iii) 아세트산, (iv) DMFO(dimethyl-formamide) 및 (v) DMSO(dimethyl sulfoxide)를 포함한다. 비극성 용매로서 적합한 것은, 아세톤, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 헥산, 2,2,4-트리메틸펜탄, 데칸, 사이클로헥산, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소 및 THF를 포함한다.When extracting cucurbitaceae used in the composition of the present invention is obtained by treating the cucurbit with an extraction solvent, various extraction solvents may be used. According to the present invention, a polar solvent or a non-polar solvent can be used. Suitable polar solvents are (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, Or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- But are not limited to, pentane, 1-chlorobutane, 1-chloropentane, o -xylene, diisopropyl ether, 2-chloropropane, toluene, 1- chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, Methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF.
본 발명의 일 구현예에 따르면, 본 발명에서 이용되는 추출용매는 (a) 물, (b) 탄소수 1-4의 무수 또는 함수 저급 알코올(메탄올, 에탄올, 프로판올, 부탄올 등), (c) 상기 저급 알코올과 물과의 혼합용매, (d) 아세톤, (e) 에틸 아세테이트, (f) 클로로포름, (g) 부틸아세테이트, (h) 1,3-부틸렌글리콜, (i) 헥산 및 (j) 디에틸에테르를 포함한다. 본 발명의 다른 구현예에, 본 발명의 추출물은 물, 에탄올 또는 이의 조합을 천궁에 처리하여 수득한 것이다. 본 발명의 특정 구현예에 따르면, 본 발명의 추출물은 천궁에 60-80 부피% 주정(grain alcohol)을 처리하여 수득한 것이다.According to an embodiment of the present invention, the extraction solvent used in the present invention may be selected from the group consisting of (a) water, (b) an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, (E) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane, and (j) Diethyl ether. In another embodiment of the present invention, the extract of the present invention is obtained by treatment with water, ethanol or a combination thereof. According to a specific embodiment of the present invention, the extract of the present invention is obtained by treating 60-80 volume% of grain alcohol in the crown mantle.
본 발명에서 이용되는 천궁 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The extract of T. kansen which is used in the present invention can be prepared in powder state by an additional process such as vacuum distillation and freeze-drying or spray drying.
본 명세서에서 사용되는 용어 ‘추출물’은 상술한 바와 같이 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 천궁 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 천궁 추출물에 포함되는 것이다.As used herein, the term " extract " means that it is used in the art as a crude extract as described above, but broadly includes fractions obtained by further fractionating the extract. That is, the extracts of cilomnia are not only obtained using the above-mentioned extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained through the purification method is also included in the cucurbitaceae extract of the present invention.
본 명세서에서 용어 ‘유효성분으로 포함하는’이란 하기의 천궁 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명은 조성물은 천연식물재료인 천궁으로부터 수득한 추출물을 포함하는 것으로서 과량 투여하여도 인체에 부작용이 없으므로 천궁 추출물이 본 발명의 조성물에 포함된 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve the efficacy or activity of the following citrus extracts. Since the composition of the present invention contains the extract obtained from the natural plant material, the extract has no adverse effect on the human body even when it is administered in an excessive amount. Therefore, the quantitative upper limit of the extract of the extract of the present invention is selected by a person skilled in the art .
본 발명에서 용어 “통증(pain)”은 넓은 의미로 사용되며, 통각수용성 통증과 같은 급성 및 만성 통증, 예컨대 체성 통증(somatic pain) 및 내장성 통증(visceral pain); 염증성 통증, 기능장애 통증, 특발성 통증, 표면성 통증(superficial pain), 심부 통증(deep pain), 가려움, 신경병증성 통증, 예컨대, 중추발생성 통증(centrally generated pain) 및 말초발생성 통증(peripherally generated pain), 편두통 및 암 통증을 포함하는 모든 타입의 통증을 의미한다. The term " pain " is used in the present invention in its broadest sense and includes acute and chronic pain such as pain ache and pain, such as somatic pain and visceral pain; Pain, pain, inflammatory pain, dysfunctional pain, idiopathic pain, superficial pain, deep pain, itching, neuropathic pain such as centrally generated pain and peripherally generated pain, migraine, and cancer pain.
본 발명의 일 구현예에 따르면, 본 발명의 조성물은 신경병증성 통증에 대해 완화, 예방 또는 치료 효과를 나타낸다. According to one embodiment of the present invention, the composition of the present invention exhibits mitigation, prophylactic or therapeutic effects on neuropathic pain.
상기 용어 “통각수용성 통증(nociceptive pain)”은 신체 조직들을 손상시킬 우려가 있거나 또는 실제로 손상시키는 유해한 자극에 의해 유발되는 모든 통증을 포함하는데 사용되며, 벤 상처(cut), 타박상(bruise), 골절(bone fracture), 압궤손상(crush injury), 화상(burn) 및 이와 유사한 상처에 의한 통증을 제한 없이 포함한다. 조직 손상에 대한 통증 수용체(통각수용기, nociceptors)는 대부분 피부, 근골격계 또는 내부장기(internal organs)에 위치하고 있다. The term " nociceptive pain " is used to include all pain caused by noxious stimuli that may or may damage nervous tissues and may include ben, cut, bruise, fracture, bone pain, bone fracture, crush injury, burn, and similar wounds. Pain receptors for tissue damage (nociceptors) are mostly located in the skin, musculoskeletal or internal organs.
상기 용어 “체성 통증(somatic pain)”은 뼈, 관절, 근육, 피부 또는 결합조직(connective tissue)에서 일어나는 통증을 나타내는데 사용된다. 이러한 타입의 통증은 전형적으로 매우 국부적이다.The term " somatic pain " is used to indicate pain that occurs in bones, joints, muscles, skin or connective tissue. This type of pain is typically very localized.
상기 용어 “내장성 통증(visceral pain)”은 본 명세서에서 호흡기(respiratory), 위장기관(gastrointestinal tract) 및 췌장(pancreas)과 같은 내장장기들, 요로(urinary tract) 및 생식기관(reproductive organs)에서 일어나는 통증을 나타내는데 사용된다. 내장성 통증은 장기피막(organ capsule)의 종양 침범(tumor involvement)에 의해 유도되는 통증을 포함한다. 다른 타입의 내장성 통증은 전형적으로 유강장기(hollow viscus)의 폐색에 의해 유발되며, 간헐적 경련(intermittent cramping) 및 심한 국부 통증이 특징이다. 내장성 통증은 방광염(cystitis) 또는 역류성 식도염(reflux esophagitis)의 경우에서와 같이 염증과 관련될 수 있다.The term " visceral pain " is used herein to refer to any or all of the organs such as respiratory, gastrointestinal tract and pancreas, urinary tract and reproductive organs, Used to indicate pain that occurs. Embolic pain includes pain induced by tumor involvement of the organ capsule. Other types of visceral pain are typically caused by occlusion of the hollow viscus, characterized by intermittent cramping and severe local pain. Embolic pain may be associated with inflammation, as in the case of cystitis or reflux esophagitis.
상기 용어 “염증성 통증”은 외상(trauma), 외과수술, 감염 및 자가면역 질환 등에 의해 유발될 수 있는 활동성 염증(active inflammation)과 관련이 있는 통증을 포함한다.The term " inflammatory pain " includes pain associated with active inflammation, which may be caused by trauma, surgery, infection, and autoimmune diseases.
상기 용어 “표면성 통증(superficial pain)”은 배근(dorsal root)의 신경이 분포된 피부 분절에 따라 느껴지는 통증을 말하며, 자극을 느낀 지점에서 통증을 느끼는 직접적인 통증이다. The term " superficial pain " refers to the pain sensed by the skin segments of the nerves of the dorsal root, and is a direct pain to feel the pain at the point of stimulation.
상기 용어 “심부통증(deep pain)”은 심부 기관에서 유래되는 통증으로 조직의 성격에 따라 통증의 특징과 정도가 다르다. 통각이 특히 예민한 부분은 건(tendon), 심부근만, 인대, 관절, 골막, 혈관 및 신경이다. 일반적으로 심부통증은 감각이 둔하고 주위로 퍼지며 느껴지는 부위가 넓다. 심부나 내장 등의 통증은 그 기전이 복잡하여 표면성 통증보다 통증의 위치를 찾기 어렵고, 오심, 발한, 혈압 상승 등의 문제도 함께 나타난다. The term " deep pain " refers to pain originating from deep organs, which varies in character and degree depending on the nature of the tissue. Particularly sensitive areas of pain are tendons, pericardium, ligaments, joints, periosteum, blood vessels and nerves. In general, deep pain is dull, spreads around, and feels wide. Pain in the deep or intestine is complicated in its mechanism, making it difficult to locate the pain rather than the surface pain, and problems such as nausea, sweating, and elevated blood pressure also appear.
상기 용어 “신경병증성 통증(neuropathic pain)”은 본 명세서에서 말초 또는 중추신경계의 장애의 결과로 생기는 말초 또는 중추신경계에 의한 비정상적 과정(abnormal processing)의 감각 입력에서 비롯된 통증을 나타내는데 사용된다.The term " neuropathic pain " is used herein to denote pain resulting from sensory input of abnormal processing by the peripheral or central nervous system resulting from disturbance of the peripheral or central nervous system.
상기 용어 “시술 통증(procedural pain)”은 내과, 치과 또는 외과 시술에서 일어나는 통증을 나타내며 상기 시술은 보통 예정되어 있거나 또는 급성 외상과 관련되어 있다.The term " procedural pain " refers to pain that occurs in internal medicine, dentistry, or surgery, and the procedure is usually scheduled or associated with acute trauma.
상기 용어 “가려움(itch)”은 본 명세서에서 넓은 의미로 사용되며, 국부에 제한하여 일반적으로 설명될 수 있는 급성 간헐성 및 지속성의, 모든 타입의 가렵고 찌르는 듯한 감각들을 의미한다. 상기 가려움은 특발성, 알러지성, 대사성, 감염성, 약물-유도성, 간, 신장 질환에 기인하거나 또는 암에 의한 것일 수 있다. “소양증(Pruritus)”은 중증 가려움증(severe itching)이다.The term " itch " is used herein in its broadest sense and refers to all types of itchy, stinging sensations of acute intermittency and persistence that can be generally described by limiting to local. The itch may be due to idiopathic, allergic, metabolic, infectious, drug-induced, liver, kidney disease or by cancer. "Pruritus" is severe itching.
“환자”라 함은 임의의 동물을 의미한다. 본 발명의 일 구현예에서, 상기 환자는 인간이다. 본 발명의 조성물을 이용하여 치료될 수 있는 다른 동물들은 비-인간 영장류들(예컨대, 원숭이, 고릴라, 침팬지), 가축(예컨대, 말, 돼지, 염소, 토끼, 양, 소, 라마), 및 반려동물(예컨대, 기니피그, 래트(rats), 마우스(mice), 도마뱀, 뱀, 개, 고양이, 관상어, 햄스터 및 새)을 포함하나 이에 한정되지는 않는다.&Quot; Patient " means any animal. In one embodiment of the invention, the patient is a human. Other animals that may be treated using the composition of the invention include non-human primates (e.g., monkeys, gorillas, chimpanzees), livestock (e.g., horses, pigs, goats, rabbits, sheep, cows, llamas) But are not limited to, animals (such as guinea pigs, rats, mice, lizards, snakes, dogs, cats, ornamental fish, hamsters and birds).
신경병증성(Neuropathic), 염증성(inflammatory) 및 통각수용성(nociceptive) 통증은 병인학(etiology), 병리생리학(pathophysiology), 진단 및 처치에 있어서 차이가 있다. 통각수용성 통증은 말초감각신경(peripheral sensory neurons)의 특이적 부분(specific subset), 즉 강렬한 또는 유해한 자극에 의해 통각수용기들의 활성화에 반응하여 일어난다. 통각수용성 통증은 일반적으로 민감하고, 자기제한적(self-limiting)이며 잠재적 또는 진행 중인 조직 손상의 경고로 작용함으로서 보호의 생물학적 기능을 제공한다. 통각수용성 통증은 전형적으로 국부에 매우 제한된다. 통각수용성 통증의 예들은, 외상성(traumatic) 또는 외과수술성(surgical) 통증, 분만 진통(labor pain), 염좌(sprains), 골절(bone fractures), 화상(burns), 충돌(bumps), 타박상(bruises), 주사(injections), 치과시술(dental procedures), 피부검사(skin biopsies) 및 폐색(obstructions)을 포함하나 이에 한정되지는 않는다.Neuropathic, inflammatory, and nociceptive pain are different in etiology, pathophysiology, diagnosis and treatment. Acupuncture pain occurs in response to activation of nociceptors by a specific subset of peripheral sensory neurons, that is, intense or harmful stimuli. Acute water-soluble pain is a generally sensitive, self-limiting, and provides a biological function of protection by acting as a warning of potential or ongoing tissue damage. Pain Acceptable pain is typically very limited to locality. Examples of painful painful pain include, but are not limited to, traumatic or surgical pain, labor pain, sprains, bone fractures, burns, bumps, but are not limited to, bruises, injections, dental procedures, skin biopsies and obstructions.
염증성 통증은 수술 후(postoperative), 외상 후(post-traumatic) 통증, 관절염(류마티스성(rheumatoid) 또는 골관절염(osteoarthritis)) 통증, 및 축성 하부요통(axial low back pain)의 경우와 같이 관절(joints), 근육 및 힘줄(tendons)의 손상과 관련된 통증을 포함하는 조직 손상 또는 염증이 있는 경우에 발생하는 통증이다.Inflammatory pain is associated with joints such as postoperative, post-traumatic pain, arthritis (rheumatoid or osteoarthritis) pain, and axial low back pain. ), Pain associated with damage to muscles and tendons, or pain when there is a tissue injury or inflammation.
통각수용성 통증과 대조적으로, 신경병증성 통증은 실제 “타는 듯한(burning),” “감전된 듯한(electric),” “얼얼하거나 저린(tingling),” 또는 “쿡쿡 쑤시는(shooting)” 것으로 묘사된다. 신경병증성 통증은 종종 만성 이질통(chronic allodynia)(가벼운 터치와 같은, 보통 통증반응을 유발하지 않는 자극으로 인한 통증으로 정의된다) 및 감각과민(hyperalgesia)(정상적인 통증자극에 대한 높은 감수성으로 정의된다)에 의해 설명되며, 어떤 손상된 조직의 외관상 치료(apparent healing) 후 수개월 또는 수년 동안 지속될 수 있다.Pain In contrast to water-soluble pain, neuropathic pain is depicted as actual "burning," "electric," "tingling," or "shooting" do. Neuropathic pain is often defined as chronic allodynia (defined as pain due to stimuli that do not cause a normal pain response, such as a mild touch) and hyperalgesia (a high susceptibility to normal pain stimuli ) And may last for months or years after apparent healing of any damaged tissue.
본 발명의 조성물은 약제학적 조성물로 제공될 수 있다.The composition of the present invention may be provided as a pharmaceutical composition.
본 발명의 조성물이 약제학적 조성물로 제조되는 경우, 유효성분으로서 천궁 추출물 뿐 만 아니라, 약제학적으로 허용되는 담체를 포함한다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences(19th ed., 1995)에 상세히 기재되어 있다.When the composition of the present invention is prepared from a pharmaceutical composition, it includes not only astragalus extract as an active ingredient, but also a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다. The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the composition can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, or the like.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약제학적 조성물의 1일 투여량은 0.001-100 ㎎/㎏이다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-100 mg / kg.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화 함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art to which the present invention belongs Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
본 발명의 다른 일 양태에 따르면, 본 발명은 천궁 추출물을 유효성분으로 포함하는 통증의 완화 또는 예방용 식품 조성물을 제공한다. According to another aspect of the present invention, there is provided a food composition for relieving or preventing pain comprising astragalus extract as an active ingredient.
본 발명의 일 구현예에 따르면, 본 발명의 식품 조성물에 의해 완화 또는 예방되는 통증은 체성 통증(somatic pain), 내장성 통증(visceral pain), 염증성 통증, 기능장애 통증, 특발성 통증, 신경병증성 통증, 표면성 통증(superficial pain), 심부 통증(deep pain), 가려움, 편두통 또는 암 통증이다. According to one embodiment of the invention, the pain relieved or prevented by the food composition of the present invention is selected from the group consisting of somatic pain, visceral pain, inflammatory pain, dysfunctional pain, idiopathic pain, Pain, superficial pain, deep pain, itching, migraine or cancer pain.
본 발명의 다른 구현예에 따르면, 본 발명의 식품 조성물에 의해 완화 또는 예방되는 통증은 신경병증성 통증이다. According to another embodiment of the present invention, the pain relieved or prevented by the food composition of the present invention is neuropathic pain.
본 발명의 조성물이 식품 조성물로 제조되는 경우, 유효성분으로서 천궁 추출물 뿐 만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. When the composition of the present invention is prepared with a food composition, it contains not only astragalus extract as an active ingredient, but also components which are ordinarily added at the time of food production, for example, protein, carbohydrate, fat, nutrients, . Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 천궁 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, etc., have.
본 발명의 특징 및 이점을 요약하면 다음과 같다: The features and advantages of the present invention are summarized as follows:
(a) 본 발명은 천궁 추출물을 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물을 제공한다.(a) The present invention provides a composition for alleviating, preventing or treating pain comprising astragalus extract as an active ingredient.
(b) 본 발명의 조성물은 기 발생된 통증에 대해 완화 및 치료 효과를 가질 뿐 아니라 통증이 발생하기 이전에 대상에 투여하면 통증을 예방하는 효과를 나타낸다. (b) The composition of the present invention not only alleviates and treats the pain generated, but also has the effect of preventing pain when administered to a subject before pain occurs.
(c) 본 발명의 조성물은 정맥주사 또는 피부 도포 등의 방법이 아닌 경구 투여를 통해서도 현저한 통증 완화 효과를 나타내며, 이러한 특징을 갖는 본 발명의 조성물은 식품에 적용 가능성이 높다. (c) The composition of the present invention exhibits remarkable pain relieving effect not only by intravenous injection or skin application but also by oral administration, and the composition of the present invention having such characteristics is highly applicable to food.
도 1은 실험동물에 천궁 추출물을 경구 투여한 다음, 피부 절개 수술을 실시하고 24시간 후(POD1) 수술 부위의 통증 민감도를 기계적 이질통 평가(von frey filament test)를 통해 측정한 결과이다.
대조군(n=10) vs. 천궁 300 mg/kg(n=10), ** p<0.01
도 2는 실험동물에 천궁 추출물을 경구 투여한 다음, 피부 절개 수술을 실시하고 3일 후(POD3) 수술 부위의 통증 민감도를 기계적 이질통 평가를 통해 측정한 결과이다.
대조군(n=10) vs. 천궁 300 mg/kg(n=10), * p<0.05
도 3은 실험동물에 천궁 추출물을 경구 투여한 다음, 피부 절개 수술을 실시하고 6시간 후 실험동물이 22-27 kHz 음력대의 초음파를 발생시키는 횟수를 측정한 결과이다.
대조군(n=10) vs. 천궁 300 mg/kg(n=10), * p<0.05
도 4는 실험동물에 천궁 추출물을 경구 투여한 다음, 피부 절개 수술을 실시하고 24시간 후 실험동물이 22-27 kHz 음력대의 초음파를 발생시키는 횟수를 측정한 결과이다.
대조군(n=10) vs. 천궁 300 mg/kg(n=10), * p<0.05
도 5는 실험동물에 천궁 추출물을 경구 투여한 다음, 피부 절개 수술을 실시하고 3일-21일 후 수술 부위의 통증 민감도를 기계적 이질통 평가를 통해 측정한 결과이다.
대조군(n=10) vs. 천궁 300 mg/kg(n=10), * p<0.05, ** p<0.01, *** p<0.001
도 6은 신경 분지 결찰 손상(Spared nerve injury, SNI) 수술 전 0일 째의 통증 민감도를 기계적 이질통 평가를 통해 측정한 결과이다.
대조군(n=10) vs. 천궁 300 mg/kg(n=10)FIG. 1 shows the results of a von Frey filament test for the pain sensitivity at the surgical site after 24 hours (POD 1) after oral administration of the extract of Orthoptera japonica to an experimental animal.
Control group (n = 10) vs. Astragalus 300 mg / kg (n = 10), ** p < 0.01
FIG. 2 shows the result of measuring the pain sensitivity of the surgical site by mechanical allodynia evaluation after 3 days (POD3) after oral administration of the extract of Orthoptera japonica to an experimental animal.
Control group (n = 10) vs. Astragalus 300 mg / kg (n = 10), * p < 0.05
FIG. 3 shows the results of the measurement of the number of times the test animals were exposed to ultrasonic waves of 22-27 kHz lunar counterpart after 6 hours from the oral administration of the extract of Ornithoptera japonica to the experimental animals.
Control group (n = 10) vs. Astragalus 300 mg / kg (n = 10), * p < 0.05
FIG. 4 is a result of measuring the number of times that the test animal produces 22-27 kHz lunar ultrasound after 24 hours of skin incision operation after orally administered to the experimental animal.
Control group (n = 10) vs. Astragalus 300 mg / kg (n = 10), * p < 0.05
FIG. 5 shows the results of measuring the pain sensitivity of the surgical site through mechanical allodynia evaluation after 3 to 21 days after oral administration of the extract of Chenopodium curcumin to the experimental animals.
Control group (n = 10) vs. (N = 10), p <0.05, ** p <0.01, *** p <0.001
FIG. 6 shows the result of measurement of pain sensitivity on the 0th day before the operation of the spinal nerve injury (SNI) through mechanical allodynia evaluation.
Control group (n = 10) vs. Astragalus 300 mg / kg (n = 10)
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예Example
실험방법Experimental Method
천궁 추출물Cinnabar extract
천연물 추출물 시료는 경동시장 내에 있는 ㈜약수당(한국)에서 건조된 천궁뿌리를 원물로 구입하였으며, 추출 전 세절하여 추출하였다. 천궁 원물 100 g당 70 부피% 주정을 10배 첨가하여 80℃에서 4시간 동안 추출한 후 여액 및 잔사 추출액을 합하여 여과 후 감압 농축하였다. 모든 추출물은 여과 및 감압농축을 거쳐 동결건조한 후 분말화하여 실험에 사용하였다. Natural herbal extracts were purchased from Kangdong Market (Korea), located in Kyungdong Market. 70% by volume of 100% ginseng was added to the mixture at a rate of 10 times, and the mixture was extracted at 80 DEG C for 4 hours. The filtrate and the residue were combined, filtered and concentrated under reduced pressure. All the extracts were filtered and concentrated under reduced pressure, lyophilized and powdered for use in the experiment.
실험동물Experimental animal
Sprague-Dawley(SD) 랫트(180-230 g, 웅성)는 (주)Samtako에서 분양받아 실험동물용 사육상자에 일주일간 적응시킨 후 실험에 사용하였다. 동물의 사육은 온도 22±1℃, 습도 55± 5%, 밤낮주기(12 시간 낮/ 12 시간 밤), 조도 300 Lux의 조건하에 이루어졌으며, 사료 및 음수는 자유 급여하였다. 모든 동물들은 KFRI-IACUC(Korea Food Research Institute, Institutional Animal Care and Use Committee)의 실험동물 사용지침에 의해 관리되었다.Sprague-Dawley (SD) rats (180-230 g, male) were purchased from Samtako Co., Ltd., and were adapted for one week in an experimental animal breeding box. The animals were fed under the conditions of temperature 22 ± 1 ℃, humidity 55 ± 5%, day and night cycle (12 hours day / 12 hours night), illumination 300 lux, feed and water free. All animals were managed by the KFRI-IACUC (National Food Research Institute, Laboratory Animal Care and Use Committee) guidelines.
시료조제 및 투여Sample preparation and administration
적응 후 정상으로 판단된 동물에 대하여 체중을 측정하고 무작위적으로 실험군을 분리하였으며, 실험동물의 개체식별은 피모색소표시법을 이용하여 실시하였다. 천궁 70% 주정 추출물 시료는 2차 증류수에 적정 농도로 용해 및 현탁시켜 제조하였다. 제조된 시료는 수술 30분 전 300 mg/kg/5 ml의 용량으로 경구투여 하였으며, 대조군은 동량의 2차 증류수를 수술 30분 전 경구투여 하였다.Body weight was measured for normal animals after the adaptation, and the experimental group was randomly selected. The animal identification of the experimental animals was carried out using the pigment coloring method. The extracts of 70% ethanol were prepared by dissolving and suspending the extracts in the second distilled water. The samples were orally administered at a dose of 300 mg / kg / 5
통증 동물모델 제작Pain modeling
피부 절개 모델(skin incision model)Skin incision model
랫트 피부 절개모델은 Brennan에 의해 제안되었다(Brennan, 1996). 일반적으로 수술 후 통증은 급성통증의 한 형태로 생각되고 있으며, 랫트의 절개모델은 인간의 수술 후 통증 상태와 유사하다고 생각되고 있다. 펜토바르피탈을 이용하여 SD 웅성 랫트(180-230 g)를 전신마취 하고 왼쪽 발바닥을 10% 포비돈액으로 소독 후 발 뒤꿈치 끝부분 0.5 cm 떨어진 부분에서 시작하여 세로방향으로 1 cm 길이의 피부와 근막을 11번 수술용 칼로 절개하였다. 절개한 부분의 발바닥 근육(족저근)을 포셉으로 들어 올려 1 cm 길이를 분리하였다. 세로방향의 양쪽 끝부분은 발바닥 근육이 떨어지지 않게 조심해서 들어 올려 분리하고 절개된 부분을 부드럽게 압박하여 지혈하였다. 지혈된 절개부위의 근막과 피부는 나일론 4-0 봉합사로 봉합 후 10% 포비돈액으로 소독하였다. 수술 후 감염방지를 위해 항생제 연고를 도포하고, 사육케이지에 옮겨 회복시켰다. 관찰기간 중 감열이 발생하거나, 봉합부위가 터진 동물과 부종이 생긴 동물은 실험에서 제외시켰다. A rat skin incision model was proposed by Brennan (Brennan, 1996). Generally, postoperative pain is thought to be a form of acute pain, and the incision model of the rat is thought to be similar to the postoperative pain state in humans. SD male rats (180-230 g) were anesthetized with pentobarbital and the left footpad was disinfected with 10% povidone solution and then started at a distance of 0.5 cm from the tip of the heel. The skin and fascia Were incised with a No. 11 surgical knife. The plantar muscle (plantar muscle) of the incision was lifted with a forceps to separate a length of 1 cm. At both ends of the vertical direction, the foot muscles were lifted carefully to avoid falling, and the bleeding was performed by gently pressing the incision. The fascia and skin of the bleeding incision site were closed with nylon 4-0 suture and disinfected with 10% povidone solution. After surgery, antibiotic ointment was applied to prevent infection and transferred to a cage for restoration. Animals that developed fever during the observation period, or sutures and edema were excluded from the study.
신경 분지 결찰 손상(Spared nerve injury, SNI) Spinal nerve injury (SNI)
신경 분지 결찰 손상 동물모델은 Decosterd 및 Woolf에 의해 제안되었다(Decosterd & Woolf, 2000). 펜토바르피탈을 이용하여 SD 웅성 랫트(180-230 g)를 전신마취 하였다. 전신마취 하에서 랫트의 좌측 넓적다리의 측면 피부를 면도하고 절개하고 대퇴이둔근(biceps femoris)을 분리한 후 좌골신경의 세 말단분지를 노출시켰다. 좌골신경은 비복신경(sural nerve), 총비골신경(common peroneal never), 경골신경(tibial nerve)의 세 가닥의 신경으로 이루어져있다. 이중 비복신경은 손상을 가하지 않고 온전히 유지해야하는데 좌측다리 기준에서 관찰시 오른쪽으로 분기해 있으며, 가장 작은 신경이다. 총비골신경, 경골신경은 다리 방향으로 근육을 따라 분기해 있으며, 각각 분리하여, 나일론 4-0 봉합사를 이용하여 단단히 결찰한 후, 포셉과 가위를 이용하여 2-4 mm 길이를 절단하여 제거하였다. 신경절단을 마무리 한 후, 근육층을 봉합사로 봉합한 다음, 피부 절개부위를 다시 봉합하여 실험동물을 사육케이지로 옮겨 회복시켰다. The nerve branch ligation impaired animal model was proposed by Decosterd and Woolf (Decosterd & Woolf, 2000). SD male rats (180-230 g) were anesthetized using pentobarbital. Under general anesthesia, the lateral skin of the left thigh of the rat was shaved, incised, and the biceps femoris separated and exposed to the three terminal branches of the sciatic nerve. The sciatic nerve consists of three nerves of the sural nerve, the common peroneal nerve, and the tibial nerve. The double sympathetic nerve should remain intact without damage, branching to the right when viewed from the left leg reference, and the smallest nerve. The total peroneal nerve and tibial nerve branching along the muscles in the leg direction were separated and ligated firmly using nylon 4-0 suture and then cut by 2-4 mm length using forceps and scissors . After finishing the nerve cutting, the muscle layer was sutured with a suture, and the skin incision site was closed again, and the experimental animals were transferred to a breeding cage to recover.
평가방법Assessment Methods
기계적 이질통 평가(von frey filament test)Von frey filament test
동물통증모델 제작 후 기계적 이질통의 정도를 측정하기 위한 방법으로 Chaplan 등에 의해 기술되었다(Chaplan et. al, 1994). 랫트를 그물눈의 크기가 2×2 mm 인 철망 실험대 위에 설치된 아크릴 상자에 넣고 15분 이상 적응시킨 뒤, 랫트의 움직임 등이 조용해지면 연속된 굵기의 본 프레이 필라멘트(Stoelting, 미국)를 사용하여 통증 역치(g) 값을 평가하였다. 필라멘트를 좌측 환부 발바닥에 수직으로 접촉시키고 5-6초간 유지시켜 랫트가 신속한 회피반응을 보이거나 또는 hairs를 떼면서 즉시 움찔하거나 발바닥을 핥으면 양성반응을 보인 것으로 간주한다. 중앙부의 본 프레이 필라멘트부터 자극하여 양성반응을 보이면 약한 필라멘트로 자극하고, 양성반응이 없으면 강한 필라멘트로 자극하며 진행한다. 양성반응을 나타내는 최소의 자극 크기를 역치로 하며, 15 g 이상에서도 반응이 없을 때를 상한선으로 하여 더 이상 적용하지 않는다.A method for measuring the degree of mechanical allodynia after animal pain modeling has been described by Chaplan et al. (Chaplan et al., 1994). The rats were placed in an acrylic box mounted on a wire mesh test bench with a mesh size of 2 x 2 mm and adapted for at least 15 minutes. When the movement of the rats was quiet, the continuous whitening prefilament (Stoelting, USA) (g) were evaluated. The filament is contacted vertically on the left footpad and maintained for 5-6 seconds, and the rat is regarded as showing a positive avoidance reaction or showing a positive response if it immediately flaps or licks the foot as the hairs are released. Stimulate with weak filaments when stimulating positive filaments from central filaments, stimulating with weak filaments, and stimulating with strong filaments. The minimum stimulation size for positive reactions should be considered as a threshold, and the upper limit should not be applied when there is no reaction even at 15 g or more.
초음파 발성음(ultrasonic vocalization calls)Ultrasonic vocalization calls
랫트는 통증, 고통, 위축, 스트레스 상태에 있을 때 초음파를 발생시키며, 그 초음파 범위는 22-27 KHz 로 보고되고 있다(Portfors, 2007). 수술 후 3.5 시간, 6 시간 및 24 시간의 통증 정도를 알아보기 위하여 각 10분 동안 USV 측정 시스템(Sonotrack, ver 1.5.0, Metris, 네덜란드) 장비를 이용하여 통증을 느낄 때 랫트가 내는 초음파(22-27 KHz) 발성음을 측정하였다. 초음파를 측정할 수 있는 아크릴 상자에 랫트를 넣어두고 15분 동안 안정화 시킨 후 10분 동안 초음파 측정 실험을 진행하였다.Rats produce ultrasound when they are in pain, distress, atrophy or stress, and their ultrasound range is reported to be 22-27 KHz (Portfors, 2007). To assess the degree of pain at the 3.5, 6, and 24 hours postoperatively, USV measurement system (Sonotrack, ver 1.5.0, Metris, Netherlands) was used for 10 minutes each. Ultrasound -27 KHz). The rats were placed in an acrylic box capable of measuring ultrasound, stabilized for 15 minutes, and ultrasonic measurement was conducted for 10 minutes.
실험결과Experiment result
천궁 300 mg/kg의 기계적 이질통 평가(von frey filament test)를 통한 통증 완화 평가Assessment of pain relief by von Frey filament test of cinnabar 300 mg / kg
피부 절개 수술 후 1일(POD1) 수술 부위의 통증 민감도를 측정하기 위하여 기계적 이질통 평가를 하였다. 그 결과, 대조군의 기계적 회피 역치(Mechanical withdrawal threshold)(g) 값이 2.333±0.910(g)인데 비하여 천궁 300 mg/kg 군은 7.600±0.748(g)로 통증을 느끼는 힘의 크기가 유의적(p<0.01)으로 증가함을 확인하였다. 또한, 수술 후 3일(POD3) 통증 역치 결과 대조군의 기계적 회피 역치(g) 값이 2.133±0.945 (g)인데 비하여 천궁 300 mg/kg 군은 6.000±0.894(g)로 통증을 느끼는 힘의 크기가 유의적(p<0.05)으로 증가함을 확인하였다.Mechanical allodynia was assessed for pain sensitivity at the surgical site for 1 day (POD1) after skin incision. As a result, the mechanical withdrawal threshold value (g) of the control group was 2.333 ± 0.910 (g), while that of the 300 mg / kg group was 7.600 ± 0.748 (g) p < 0.01). In addition, the pain threshold at 3 days after surgery (POD3) was 2.133 ± 0.945 (g) in the control group and 6.000 ± 0.894 (g) in the control group, ( P <0.05), respectively.
천궁 300 mg/kg의 초음파 발성음(ultrasonic vocalization calls) 측정을 통한 통증 완화 효과 확인Determination of pain relief effect by ultrasonic vocalization calls at 300 mg / kg
피부 절개 수술 후 3.5 시간, 6 시간, 24 시간(POD1)의 시간대 별로 실험동물이 통증을 느낄 때 유발하는 초음파 음력대(22-27 kHz)를 측정 후, 그 횟수를 정량화하여 천궁의 통증 완화 효과를 확인하였다. 수술 6 시간 후, 초음파 발성음 측정값에서 대조군이 8.667±2.171(calls)인데 비하여 천궁 300 mg/kg 군은 1.200±0.200(calls)을 기록하여 유의적(p<0.05)으로 감소함을 확인하였다. 수술 후 24 시간(POD1) 초음파 발성음 측정값에서 대조군이 9.667±2.591(calls) 인데 비하여 천궁 300 mg/kg 군은 2.800±0.583(calls) 을 기록하여 유의적(p<0.05)으로 감소함을 확인하였다.The ultrasonic lunar laryngeal band (22-27 kHz) caused by the pain of the experimental animals was measured at the time of 3.5 hours, 6 hours and 24 hours (POD1) after the skin incision operation, and the number of times was quantified, Respectively. After 6 hours of operation, the ultrasound spoken sounds showed a significant decrease (p <0.05) in the control group of 8.667 ± 2.171 (calls) compared to 1.200 ± 0.200 (calls) . In the POD1 ultrasonograms, the control group was 9.667 ± 2.591 (calls) compared to the control group (POD1). The mean value of the cynomolgus 300 mg / kg group was 2.800 ± 0.583 Respectively.
천궁 300 mg/kg의 기계적 이질통 평가를 통한 통증 완화 평가(장기모델)Evaluation of pain relief through mechanical allodynia evaluation of 300 mg / kg (long-term model)
SNI 수술 후 21일 동안 장기적으로 천궁을 경구투여하며 3일 간격으로 통증 민감도를 측정하기 위하여 기계적 이질통 평가를 실시하였다. 그 결과 POD3, 대조군의 기계적 회피 역치(g) 값이 1.689±0.342(g)에 비하여 천궁 300 mg/kg 군은 6.80±0.742(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.001)으로 증가함을 확인하였다. POD6, 대조군의 기계적 회피 역치(g) 값이 0.867±0.160(g)에 비하여 천궁 300 mg/kg 군은 3.360±0.836(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.05)으로 증가함을 확인하였다. POD9, 대조군의 기계적 회피 역치(g) 값이 0.697±0.129(g)에 비하여 천궁 300 mg/kg 군은 3.880±1.014(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.01)으로 증가함을 확인하였다. POD12, 대조군의 기계적 회피 역치(g) 값이 0.429±0.123(g)에 비하여 천궁 300 mg/kg 군은 2.880±1.079(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.05)으로 증가함을 확인하였다. POD15, 대조군의 기계적 회피 역치(g) 값이 0.333±0.080(g)에 비하여 천궁 300 mg/kg 군은 2.980±0.887(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.05)으로 증가함을 확인하였다. POD18, 대조군의 기계적 회피 역치(g) 값이 0.142±0.039(g)에 비하여 천궁 300 mg/kg 군은 2.356±0.864(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.05)으로 증가함을 확인하였다. POD21, 대조군의 기계적 회피 역치(g) 값이 0.149±0.051(g)에 비하여 천궁 300 mg/kg 군은 2.176±0.742(g)으로 통증을 느끼는 힘의 크기가 유의적(p<0.05)으로 증가함을 확인하였다. 이러한 결과 천궁의 통증완화 효과는 단기모델인 피부 절개 모델 뿐 만 아니라 장기모델인 SNI 모델에서도 효과를 확인하였다.For 21 days after SNI surgery, long - term oral gavage was administered orally, and mechanical allodynia was evaluated at 3 - day intervals to measure pain sensitivity. As a result, POD3 showed a significant ( p <0.001) significant difference in pain intensity with the mechanical evasion threshold value (g) of the control group of 1.689 ± 0.342 (g) and 6.80 ± 0.742 (g) . ( P <0.05), the intensity of pain felt by POD6 was 3.360 ± 0.836 (g) at 300 mg / kg body weight of the control group, compared to 0.867 ± 0.160 (g) Respectively. POD9 showed a significant increase ( p <0.01) in the intensity of pain felt in the control group (3.880 ± 1.014 g) compared with 0.697 ± 0.129 (g) in the mechanical evasion threshold (g) Respectively. ( P <0.05), the intensity of pain felt in POD12 was significantly ( p <0.05) higher than that of control group (0.429 ± 0.123 g) in the control group and 2.880 ± 1.079 Respectively. POD15 was 2.980 ± 0.887 (g), which was significantly higher than that of the control group (0.333 ± 0.080 g) and 300 mg / kg ( p <0.05) Respectively. POD18 showed a significant ( p <0.05) increase in the intensity of the pain felt at 300 mg / kg group at 2.356 ± 0.864 (g) compared with 0.142 ± 0.039 (g) at the mechanical evasion threshold Respectively. ( P <0.05). In the control group, the mechanical evasion threshold value (g) was 0.149 ± 0.051 (g), and the mean power of 300 mg / kg group was 2.176 ± 0.742 (g) Respectively. As a result, the pain relief effect of the cynomolgus was confirmed not only in the short - term skin incision model but also in the long - term SNI model.
SNI 수술 전 두 군간의 통증에 대한 베이스라인을 확인하기 위하여 기계적 이질통 평가를 하여, 두 실험군 사이의 수술 전 기계적 회피 역치(g) 값은 같음을 확인 하였다.To confirm the baseline of the pain between the two groups before SNI, mechanical allodynia was assessed and the pre - operative mechanical avoidance threshold (g) values were confirmed to be the same between the two groups.
결론conclusion
본 발명의 천궁(Cnidium officinale Makino) 추출물은 통증 동물모델인 피부 절개 모델과 신경 분지 결찰 손상 모델에서 모두 통증을 완화시키는 효과를 확인하였으며, 특히 단기효과 뿐 만 아니라 장기효과도 확인할 수 있었다. 따라서, 본 발명의 천궁 추출물을 유효성분으로 포함하는 조성물을 이용하여 통증 예방, 완화 또는 치료하는 효과를 나타낸다.The extract of Cnidium officinale Makino of the present invention showed pain relieving effect both in the pain model animal, the skin incision model and the nerve branch ligation damage model. In particular, the short-term effect as well as the long-term effect could be confirmed. Accordingly, the present invention provides a composition for preventing, alleviating, or treating pain using the composition comprising the extract of the present invention as an active ingredient.
참고문헌references
1. Lee JH, Choi HS, Chung MS, Lee MS. Volatile flavor components and free radical scavenging activity of Cnidium officinale . Korean J Food Sci Technol 34: 330-338 (2002) 1. Lee JH, Choi HS, Chung MS, Lee MS. Volatile flavor components and free radical scavenging activity of Cnidium officinale. Korean J Food Sci Technol 34: 330-338 (2002)
2. Cho SK, Kwon OI, Kim CJ. Anti-inflammatory and analgesic activities of the extracts and fractions of Cnidii rhizoma. Kor J Pharmacogn 27: 282-287 (1996)2. Cho SK, Kwon OI, Kim CJ. Anti-inflammatory and analgesic activities of the extracts and fractions of Cnidii rhizoma. Kor J Pharmacogn 27: 282-287 (1996)
3. Zhang L, Du JR, Wang J, Yu DK, Chen YS, He Y, Wang CY. Z-ligustilide extracted from Radix Angelica Sinensis decreased platelet aggregation induced by ADP exvivo and arterio-venous shunt thombosis in vivo in rats. Yakugaku Zasshi 129: 855-859 (2009) 3. Zhang L, Du JR, Wang J, Yu DK, Chen YS, He Y, Wang CY. Z-ligustilide extracted from Radix Angelica sinensis decreased platelet aggregation induced by ADP ex vivo and arterio-venous shunt thombosis in vivo in rats. Yakugaku Zasshi 129: 855-859 (2009)
4. Brennan TJ, Vandermeulen EP, Gebhart GF. Characterization of a rat model of incisional pain. Pain 64:493-501(1996).4. Brennan TJ, Vandermeulen EP, Gebhart GF. Characterization of a rat model of incisional pain. Pain 64: 493-501 (1996).
5. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87:149-58(2000).5. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87: 149-58 (2000).
6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63(1994).6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63 (1994).
7. Portfors CV. Types and functions of ultrasonic vocalizations in laboratory rats and mice. J Am Assoc Lab Anim Sci. 46(1):28-34(2007).7. Portfors CV. Types and functions of ultrasonic vocalizations in laboratory rats and mice. J Am Assoc Lab Anim Sci . 46 (1): 28-34 (2007).
Claims (3)
A pharmaceutical composition for oral administration for alleviating, preventing or treating persistent peripheral neuropathic pain or post-surgical pain comprising a single extract of Cnidium officinale Makino as an active ingredient.
The composition according to claim 1, wherein the cucurbitaceae extract is obtained by treating cucumbers with water, methanol, ethanol or a combination thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160025104A KR101680840B1 (en) | 2016-03-02 | 2016-03-02 | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160025104A KR101680840B1 (en) | 2016-03-02 | 2016-03-02 | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140019551A Division KR20150098370A (en) | 2014-02-20 | 2014-02-20 | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160031476A KR20160031476A (en) | 2016-03-22 |
| KR101680840B1 true KR101680840B1 (en) | 2016-12-01 |
Family
ID=55644873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160025104A KR101680840B1 (en) | 2016-03-02 | 2016-03-02 | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101680840B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230021227A (en) | 2021-08-05 | 2023-02-14 | 경성대학교 산학협력단 | Method for manufacturing Parenteral formulation using Cnidii Rhizoma |
| KR20230067541A (en) | 2021-11-08 | 2023-05-16 | 계명대학교 산학협력단 | Composition for enhancing immunity comprising hot water extract of Cnidium officinale as an active ingredient |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000272666A1 (en) * | 2000-09-12 | 2002-03-26 | Jiangsu Kanion Pharmaceutical Co. | A pharmaceutical composition for treating headache disease and process and uses thereof |
| KR20110109607A (en) * | 2010-03-31 | 2011-10-06 | 이윤식 | Composition of herb medicine for reliefing and curing lumbar disc pain |
| KR101257578B1 (en) * | 2010-12-24 | 2013-04-23 | 대전대학교 산학협력단 | Herbal Medicnes for Treating Diabetic Neuropathy |
-
2016
- 2016-03-02 KR KR1020160025104A patent/KR101680840B1/en active IP Right Grant
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230021227A (en) | 2021-08-05 | 2023-02-14 | 경성대학교 산학협력단 | Method for manufacturing Parenteral formulation using Cnidii Rhizoma |
| KR20230067541A (en) | 2021-11-08 | 2023-05-16 | 계명대학교 산학협력단 | Composition for enhancing immunity comprising hot water extract of Cnidium officinale as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160031476A (en) | 2016-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumari et al. | Invitro anti-inflammatory and anti-artheritic property of Rhizopora mucronata leaves | |
| Singh et al. | Traditional uses, phytochemistry and pharmacological properties of Capparis decidua: An overview | |
| Mannelli et al. | Widespread pain reliever profile of a flower extract of Tanacetum parthenium | |
| RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
| KR101584279B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Ecklonia cava Extracts as Active Ingredients | |
| KR101680840B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients | |
| KR102151401B1 (en) | Composition for preventing or treating pain comprising extracts from Jasminum microcalyx Hance as an active ingredient | |
| Ladol et al. | The effects of Hippophae rhamnoides in neuroprotection and behavioral alterations against iron-induced epilepsy | |
| Figueredo et al. | Antinociceptive and gastroprotective actions of ethanolic extract from Pluchea sagittalis (Lam.) Cabrera | |
| KR101500485B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Ilex paraguayensis Extracts as Active Ingredients | |
| KR101938933B1 (en) | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata | |
| Yusuf et al. | Acute toxicity studies and evaluation of analgesic property of the methanol stem bark extract of Neocarya macrophylla | |
| KR101598600B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Harapagophytum procumbens and Acanthopanax senticosus Extracts as Active Ingredients | |
| KR102106325B1 (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Camellia japonica L. Extracts | |
| KR101932856B1 (en) | Korean medicine material composition for treating Chemotherapy-induced peripheral neuropathy | |
| KR101784591B1 (en) | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Vitis amurensis, Glycyrrhizae and Aralia cordata | |
| KR20150098370A (en) | Compositions for Alleviating, Preventing or Treating Pain Comprising Cnidium officinale Makino Extracts as Active Ingredients | |
| KR102234860B1 (en) | Composition for prevention and treatment of muscle atrophy comprising lespedeza bicolor extract | |
| KR20130074807A (en) | Cosmetics having muskrat musk | |
| WO1991008750A1 (en) | Use of parts of the natural plant tinospora | |
| CN114668809B (en) | Medicine for improving shaping and beautifying side effects | |
| KR20130031773A (en) | Lipid water soluble bee venom extracts for improving immunity and for curing inflammation and for curing pain and composition for parenteral medicines and manufacturing method of the same | |
| KR20130129616A (en) | Composition comprising aged honey, mulberry and eucommiae cortex for preventing or treatment of arthritis | |
| Nwinyi et al. | Evaluation of aqueous-methanol stem bark extract of Stereospermum kunthianum Cham.(Family: Bignoniaceae) for Anti-inflammatory and antinociceptive effects | |
| KR102073796B1 (en) | Composition for preventing or treating pain comprising extracts from Combretum farinosum Kunth as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 4 |